<DOC>
	<DOCNO>NCT01920061</DOCNO>
	<brief_summary>This study evaluate PF-05212384 ( PI3K/mTOR inhibitor ) combination either docetaxel , cisplatin dacomitinib select advance solid tumor . The study ass safety , pharmacokinetics pharmacodynamics combination patient advance cancer order determine maximum tolerate dose combination .</brief_summary>
	<brief_title>A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Arm A : castrate resistant prostate cancer , advance breast cancer , nonsmall cell lunch cancer candidate treatment docetaxelbased combination . Arm B : Urothelial transitional cell cancer , triple negative breast cancer , ovarian cancer non small cell lunch cancer candidate cisplatinbased combination . Arm C : Her2+ breast cancer refractory prior herceptin lapatinib , her2+ esophagalgastric cancer , head neck squamous cell cancer , non small cell lunch cancer candidate treatment dacomitinibbased combination . Availability archival tumor biopsy sample willing provide fresh biopsy available . Eastern Cooperative Oncology Group [ ECOG ] performance must 0 1 . Adequate bone marrow , renal liver function . Patients know symptomatic brain metastasis . Chemotherapy , radiotherapy , biologics investigational agent within 4 week leadin dose . Major surgery within 4 week baseline disease assessment . &gt; 2 prior regimen contain cytotoxic chemotherapy metastatic setting . Active bacterial , fungal viral infection . Uncontrolled significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>PI3K</keyword>
	<keyword>mTOR</keyword>
	<keyword>PI3K/mTOR</keyword>
	<keyword>metastatic</keyword>
</DOC>